Ellegaard Göttingen Minipigs Enters into a License and Commercialization Agreement for Göttingen Minipigs Research Models in Partnership with Exemplar Genetics

Dalmose, Denmark, 26 November 2018

Ellegaard Göttingen Minipigs A/S, today announced the signing of a license and commercialization agreement with Exemplar Genetics to develop and commercialize genetically modified Göttingen Minipigs models of human disease on a target-by-target basis. Göttingen Minipigs are a small, docile, microbiologically and genetically well-defined large animal model recognized by the global biomedical research community and regulatory authorities, making Göttingen Minipigs the genetics of choice for preclinical studies.

“At Ellegaard Göttingen Minipigs, we are looking forward to working with Exemplar in providing genetically modified animal models based on our high-quality and well-defined Göttingen Minipigs,” said Dr. Lars Friis Mikkelsen, CEO of Ellegaard Göttingen Minipigs.

“Adding Göttingen Minipig genetics to our offerings will allow us to better serve our customer needs,” said Dr. John R. Swart, President of Exemplar Genetics. “We are very excited to partner with Ellegaard Göttingen Minipigs in providing models to the research community that we believe will translate well to the clinic.”

About Ellegaard Göttingen Minipigs

Ellegaard Göttingen Minipigs A/S is the breeder and global provider of Göttingen Minipigs for biomedical research focusing on the advancement of quality of life and health. The company has high standards of animal welfare, health, quality, knowledge and service and has for decades been fully AAALAC-accredited. For more information, visit https://minipigs.dk/

About Exemplar Genetics

Exemplar Genetics, a wholly owned subsidiary of Intrexon Corporation (NASDAQ: XON), enables discovery by providing models and services that aid scientists in the development of next-generation procedures, devices and therapeutics. Through its innovative models and AAALAC-accredited facilities, Exemplar Genetics assists researchers in making advances in the discovery of human disease mechanisms, the optimization of novel diagnostics, and the development of new treatments. For more information, visit www.exemplargenetics.com.

General Inquiries
Dr. Lars Friis Mikkelsen, CEO, Ellegaard Göttingen Minipigs A/S lfm@minipigs.dk

Media Inquiries
Søs Pihl-Poulsen, Management Assistant, Ellegaard Göttingen Minipigs A/S spp@minipigs.dk